Aurion raises $120M in bid to scale cell therapy for form of blindness
To treat corneal endothelial dysfunction, a condition that causes the outer layer of the eye to swell and go hazy, doctors generally rely on cell transplants.
A highly-trained surgeon rolls out an incredibly thin scroll of cells — around the width of a single strand of hair — from a donor into the patient’s eye, holding it in place with a tiny air bubble.
Each donor can only help one patient, and the patient then has to lie still for at least a day after surgery so as to not disturb the air bubble holding their new corneal endothelium in place.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.